



## RESEARCH ARTICLE

# Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya. [version 1; peer review: 2 approved, 2 approved with reservations]

Joyce U. Nyiro <sup>1</sup>, Patience K. Kiyuka<sup>1</sup>, Martin N. Mutunga<sup>1</sup>, Charles J. Sande <sup>1</sup>, Patrick K. Munywoki <sup>2</sup>, J. Anthony G. Scott <sup>1,3</sup>, D. James Nokes <sup>1,4</sup>

<sup>1</sup>Epidemiology and Demography, Kenya Medical Research Institute-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya

<sup>2</sup>Kenya Center for Disease Control and Prevention, Nairobi, Kenya

<sup>3</sup>Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

<sup>4</sup>School of Life Sciences and Zeeman Institute (SBIDER), University of Warwick, Coventry, UK

**v1** First published: 18 Feb 2019, 4:33 (<https://doi.org/10.12688/wellcomeopenres.15108.1>)

Latest published: 18 Feb 2019, 4:33 (<https://doi.org/10.12688/wellcomeopenres.15108.1>)

## Abstract

**Background:** Severe disease associated with respiratory syncytial virus (RSV) infection occurs predominantly among infants under 6 months of age. Vaccines for prevention are in clinical development. Assessment of the vaccine effectiveness in large epidemiological studies requires serological assays which are rapid, economical and standardised between laboratories. The objective of this study was to assess the agreement between two enzyme linked immunosorbent assays (ELISA) and the plaque reduction neutralisation test (PRNT) in quantifying RSV specific antibodies.

**Methods:** Archived sera from 99 participants of the Kilifi Birth Cohort (KBC) study (conducted 2002-2007) were screened for RSV antibodies using 3 methods: ELISA using crude RSV lysate as antigen, a commercial RSV immunoglobulin G (IgG) ELISA kit from IBL International GmbH, and PRNT. Pearson correlation, Bland-Altman plots and regression methods were used in analysis.

**Results:** There was high positive correlation between the IBL RSV IgG ELISA and PRNT antibodies (Pearson  $r=0.75$ ), and moderate positive correlation between the crude RSV lysate IgG ELISA and PRNT antibodies ( $r=0.61$ ). Crude RSV lysate IgG ELISA showed a wider 95% limit of agreement (-1.866, 6.157) with PRNT compared to the IBL RSV IgG ELISA (1.392, 7.595). Mean PRNT titres were estimated within a width of  $4.8 \log_2$  PRNT and  $5.6 \log_2$  PRNT at 95% prediction interval by IBL RSV IgG and crude RSV lysate IgG ELISA, respectively.

**Conclusion:** Although, the IBL RSV IgG ELISA is observed to provide a reasonable correlate for PRNT assay in detecting RSV specific antibodies, it does not provide an accurate prediction for neutralizing antibody levels. An RSV neutralising antibody level is likely to fall within 2.4 fold higher and 2.4 fold lower than the true value if IBL RSV IgG ELISA is used to replace PRNT assay.

## Open Peer Review

Referee Status:

	Invited Referees			
	1	2	3	4
version 1 published 18 Feb 2019	report	report	report	report

- 1 **Ting Shi** , University of Edinburgh, UK
- 2 **Shabir Madhi** , University of Witwatersrand, South Africa
- 3 **Helen Y. Chu**, University of Washington, USA
- 4 **Pedro A. Piedra**, Baylor College of Medicine, USA

Any reports and responses or comments on the article can be found at the end of the article.

The utility of an ELISA assay in vaccine studies should be assessed independent of the PRNT method.

### Keywords

Respiratory syncytial virus, specific antibody, serological assays, agreement, birth cohort.



This article is included in the [KEMRI | Wellcome Trust gateway](#).

**Corresponding author:** Joyce U. Nyiro ([JNyiro@kemri-wellcome.org](mailto:JNyiro@kemri-wellcome.org))

**Author roles:** **Nyiro JU:** Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation; **Kiyuka PK:** Investigation, Writing – Review & Editing; **Mutungu MN:** Investigation, Writing – Review & Editing; **Sande CJ:** Conceptualization, Investigation, Writing – Review & Editing; **Munywoki PK:** Conceptualization, Methodology, Writing – Review & Editing; **Scott JAG:** Formal Analysis, Funding Acquisition, Writing – Review & Editing; **Nokes DJ:** Conceptualization, Funding Acquisition, Methodology, Resources, Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by the Wellcome trust [102975 and 084633]. This work was also supported by PATH [GAT.1387-05695-COL]

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Nyiro JU *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Nyiro JU, Kiyuka PK, Mutunga MN *et al.* **Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya. [version 1; peer review: 2 approved, 2 approved with reservations]** Wellcome Open Research 2019, 4:33 (<https://doi.org/10.12688/wellcomeopenres.15108.1>)

**First published:** 18 Feb 2019, 4:33 (<https://doi.org/10.12688/wellcomeopenres.15108.1>)

## Introduction

Respiratory syncytial virus (RSV) is an important cause of annual epidemics of bronchiolitis and pneumonia in children less than five years of age worldwide<sup>1-5</sup>. The most severe disease occurs among infants under 6 months of age<sup>6</sup>, making this group the principal target for RSV disease prevention.

To date there are no licensed vaccines for RSV. However, strategies to protect the young infant through immunisation are underway. One approach showing particular promise is to protect the infant over the first few months of life by maternal vaccination. A maternal RSV vaccine which is based on a post-fusion F protein nanoparticle design<sup>7</sup>, is now undergoing phase 3 clinical trials (NCT02624947). Standardised serological assays are needed if this or other vaccines show good efficacy as they go to effectiveness phase 3b/4 clinical trials.

The plaque reduction neutralisation test (PRNT) has been the preferred technique by most studies to determine the correlates of protective immunity to RSV<sup>8-13</sup>. This is because the assay determines the level of antibodies present that are presumed to be functional *in vivo*<sup>14</sup>. For instance, a pseudovirion-based neutralisation assay was found to detect all neutralizing antibodies that directly arrest the virus and thus to provide protection against infection with Human papilloma virus<sup>15</sup>. A study by Piedra *et al.* showed that serum antibody titres correlate with protection<sup>8</sup>; a finding also supported by Stansbelle *et al.* who showed that neutralisation antibody titres were inversely associated with RSV hospitalization in infants <6months<sup>16</sup>. Hence PRNT is considered the most appropriate serological assay for use in quantifying protective immunity correlates to RSV.

Although the PRNT is considered the “Gold standard” method for quantifying the level of RSV specific antibodies, it has several limitations: (i) PRNT antibody titres are currently not internationally standardised and therefore it is difficult to compare results across different studies, though work is under way to resolve this<sup>17</sup>; (ii) the assay procedure is cumbersome - taking four to six days (according to method) to complete; and, (iii) the assay is costly in terms of laboratory technologist time. Hence, the PRNT is not ideal for large sero-epidemiological studies or large-scale vaccine trials.

Due to these limitations, it would be beneficial to adopt a serological assay which is quicker, cheaper and can be easily standardized, for use in large vaccine studies. An ELISA method is an option. However, the method measures epitopes of the target antigen and does not discriminate antibodies specific to neutralizing sites. Presently, there are two RSV specific IgG ELISA assays in our laboratory: an ELISA which uses crude RSV A2 culture lysate as antigen (Crude ELISA), and a commercial ELISA (IBL ELISA) which uses 96 well micro titre ELISA plates pre-coated with RSV F protein and RSV group A cell extract as antigen. We examined the agreement between ELISA assays and the PRNT in quantifying RSV specific antibodies using serum samples from a birth cohort in Kilifi, a coastal part of Kenya.

## Methods

### Study site and participants

This study was conducted in Kilifi, within the Kilifi Health and Demographic Surveillance System (KHDSS) in the coastal part of Kenya<sup>18-20</sup>. Archived serum and plasma samples were utilised arising from the Kilifi Birth Cohort (KBC) study conducted between 2002 and 2007, by the Kenya Medical Research Institute-Wellcome Trust Research Programme (KEMRI-WTRP). The KBC study was an observational study to investigate susceptibility to invasive pneumococcal disease among children. In this study, newborn participants numbering around 6000, recruited at the maternity ward or the child health clinic of Kilifi County Hospital (KCH), were followed for a 2-year period with blood samples collected at birth and then every 3 months. Samples were stored as plasma (for cord bloods) or serum (follow-up samples) at -80°C. Details of the birth cohort study are described elsewhere<sup>10,18,19</sup>.

In the present study, a random sample set of 100 individuals from the KBC participants recruited from the KCH maternity ward, were selected from the study database. Description of the levels of maternal RSV specific neutralizing antibodies from blood samples of the 100 participants were provided in a previous publication<sup>10</sup>.

### Ethical considerations

All parents and guardians gave written consent to have their children participate in the KBC study for storage of blood samples for use in future research. The use of the archived sample set was approved by the KEMRI-Scientific and Ethics Review Unit (SERU# 2307).

### Laboratory procedures

Archived plasma/serum samples from the KBC study which had been stored at -80°C were retrieved and screened using 3 serological assay techniques: (i) a PRNT (ii) an IgG ELISA assay using crude RSV lysate as antigen (crude ELISA) and (iii) an RSV IgG ELISA using a commercial ELISA kit (IBL ELISA).

**Plaque reduction neutralisation test (PRNT).** The PRNT procedure for determining the titre of RSV neutralising antibodies has been described previously<sup>9</sup>. The method incorporated a step in which serum samples were incubated at 56°C in a water bath for 30 minutes to inactivate complement cascade proteins. Each serum sample was repeatedly diluted 2-fold over ten consecutive dilutions and mixed with an equal volume of 50 plaque forming units (pfu) of RSV A2 virus (RSVA2 and Hep2 cells were a kind donation from Dr. Patricia Cane while she worked at the Health Protection Agency, UK). The virus-serum mixture (50µl per well) was dispensed over a confluent monolayer of Hep2 cells in a 96 well culture plate, incubated at 37°C for 1 hour and then underwent 4-hour cycles of rotation on an angled (about 30°) rotating platform (about 40 rev/minute) for 10 minutes and incubation in a 37°C CO<sub>2</sub> incubator for 30 minutes. The plate was then incubated for 48 hours in a 37°C CO<sub>2</sub> incubator. Fixation of cells was done by the addition of 100µl of fixation reagent (30% methanol+70% acetone). Plaques

were detected by addition of a primary antibody (RSV F protein mouse monoclonal-BIO-RAD, Catalogue# MCA490) solution diluted 1:500 in PBS with 2 hours incubation at 37°C, followed by an addition of a 100µl/well of an anti-mouse HRP-conjugated secondary antibody (170-5047 Immun-Star Goat Anti-Mouse (GAM)- IgG (H/L) polyclonal antibody HRP-BIORAD) solution diluted 1:1000 in Phosphate Buffered Saline (PBS) with 1 hour incubation at room temperature. After each step, plates were washed manually three times using 200µl/well PBS buffer. Plaques were visualised by addition of 100µl/well detection reagent. This consisted of 16 µl of hydrogen peroxide and 0.6ml of 3-amino-9-ethylcarbazole 3.3mg/ml solution (20mg 3-amino-9-ethylcarbazole tablet were dissolved in 6.06ml of dimethyl sulphoxide (DMSO) to give a 3.3mg/ml solution) to 10ml of 20mM sodium acetate solution (pH 5.0-5.5). Reading and counting of the brown-stained RSV micro-plaques was done using an ELISpot reader (Autoimmun Diagnostika GmbH, Germany).

The dilution of a test serum sample required to induce 50% neutralization of a known titration of RSV A2 virus was determined using the Spearman Karber method<sup>9</sup>. In addition, a panel of control samples from BEI Resources (BEI RSV Reference panel catalogue #NR-32832) was included in each batch of the PRNT assay to monitor reproducibility of the assay results and deterioration of the antibodies used. Results obtained from screening of the BEI samples were compared with PRNT values of the samples as previously tested in BEI resources laboratories.

**Crude RSV lysate IgG ELISA (Crude ELISA).** Blood samples were tested for antibody concentration with an IgG based ELISA method using crude virus extract from lab-adapted RSV A2 culture following a local standard operating procedure<sup>21</sup>. The crude virus RSV lysate preparation, optimal dilutions for RSV-A2 antigen, the serum dilutions and generation of a standard curve from a pooled adult serum were determined by a checkerboard titration as previously described<sup>21,22</sup>. In every run, one half of the 96 well plate (column 1-6) was coated with 50µl/well of RSV lysate (antigen), while the other half (column 7-12) was coated with 50µl/well of mock lysate (mock). The mock consisted of Hep2 cells without RSV virus prepared using same procedure as that of the RSV lysate. Plates were incubated overnight at 37°C, then blocked for 1 hour with 200µl/well of 5% skimmed milk at 37°C. Blocking buffer was flicked off. Diluted serum samples 100µl/well were dispensed to both the antigen and mock sides of the plate. The plates were washed 4 times with 200µl/well of 0.05% Tween 20 in PBS (PBS-T) using an ELISA plate washer. A secondary antibody [polyclonal antibody to human IgG heavy chains (Goat anti human IgG HRP antibody-KPL, Catalogue# 074-1002) (100µl/well) diluted 1:1000 in PBS buffer was added to each well and incubated for 1 hour at room temperature. The reaction was developed using 50µl/well of Ortho-Phenylenediamine dihydrochloride (OPD, Catalogue# P8412-100TAB, Sigma-Aldrich) solution as substrate (prepared just before use in the ratio 1mg of OPD in 1 ml of PBS and 1ul of hydrogen peroxide). The intensity of colour developed was read at 490nm using an ELISA reader

(SYNERGY 4, BioTeK). All samples were run in duplicate to monitor reproducibility of results and variability arising from pipetting. Positive and negative controls were run on every plate and plotted on a graph over time to check for antigen deterioration of the standards or coating antigen. The OD values of the mock were subtracted from the OD values of the antigen lysate to give the final OD value of the serum sample. OD values of the standard serum dilutions were assigned arbitrary unit (AU) values. Serum samples were assigned arbitrary units of RSV specific IgG by comparison against a standard curve generated from the pooled adult serum (serum standard) tested in each ELISA plate.

**Commercial RSV IgG ELISA (IBL ELISA).** Use of the commercial RSV IgG ELISA kit and the procedure followed manufacturer's guidelines as described in the package insert (Cat#: RE56881- IBL International GmbH, D-22335 Hamburg, Germany). The ELISA procedure was based on a sandwich principle. In this assay, the 96 well plates were pre-coated with Vero E6 cells; strain long, F-protein; cell extract of RSV subgroup A (long strain) containing F-protein as well as G-protein as antigen (IBL communication). Specific antibodies from the serum samples binding to the pre-coated antigen were detected by a secondary antibody, rabbit anti-human conjugated to horse radish peroxidase enzyme. The reaction was developed using Tetramethylbenzidine(TMB) solution as substrate. The intensity of the colour developed, which is proportional to the concentration of IgG-specific antibodies detected, was read at 450nm using an ELISA reader (SYNERGY 4, BioTeK). The concentration of RSV IgG antibodies from the samples was estimated by comparison with a standard curve fit using a four parameter logistic regression model conducted in a [GraphPad Prism](#) software version 7.03.

### Statistical analyses

Data analysis was conducted using [STATA](#) version 13.1 (College Station, Texas). The laboratory data were merged with archived data from the KBC participant' databases for analysis. Sample PRNT titres were logarithmically transformed (base 2) for all statistical analyses.

Correlation analyses between PRNT antibodies ( $\log_2$ PRNT) and IgG ELISA ( $\log_{10}$ ) antibodies was done using a Pearson correlation test. Agreement between PRNT and ELISA was done using Bland-Altman plots<sup>23</sup>. For each serum sample, the difference between PRNT and ELISA result was plotted against the averages of both assays. During Bland-Altman analysis, concentrations for RSV IgG IBL ELISA and crude lysate RSV IgG ELISA were log transformed to (base 2) and the data tested for normality. Modified Bland-Altman plots were used to test the effect of age on agreement between ELISA and PRNT. Regression analysis between ELISA and PRNT was used to estimate the 95% prediction intervals of PRNT antibodies by IgG ELISA method. The standard error (SE) of the predicted PRNT titre for an individual was estimated using the formula:

$$SE = \sqrt{(RMS \left(1 + \frac{1}{n}\right))},$$

Where, RMS is the residual mean squares and  $n$  is the number of observations. The predicted mean of PRNT titre by an ELISA method was calculated using the formula:

$$y = mx + c,$$

Where  $y$  is the predicted PRNT titre,  $m$  is the regression coefficient,  $x$  is the RSV antibody concentration by ELISA measurement and  $c$  is the  $y$  intercept where  $x=0$ . The upper and lower 95% prediction intervals were calculated using the formula: Upper/Lower 95% prediction limit =  $(mx+c) \pm 1.96SE$ , where SE is the standard error (see full methods [here](#)).

## Results

### Baseline characteristics

Archived sera from 100 cohort participants were selected. However, for 1 participant, the samples were not sufficient to screen for ELISA IgG antibodies after screening for PRNT titres. A total of 229 samples (99 cord samples, 87 three-month samples and 43 six-month samples) from the 99 participants were therefore available with data for the 3 serological assays. The mean gestational age at birth was 38.5 weeks (95% CI 37.6 – 39.3), while the mean birth weight was 2.9 kilograms (95% CI 2.7 – 3.0). The mean concentration of  $\log_2$ PRNT titres were: cord blood samples, 10.6  $\log_2$ PRNT (95% Confidence interval, CI; 10.3– 10.8); 3 months of age samples; 8.3  $\log_2$ PRNT (95% CI 8.1 – 8.6); and 6 months and over 7.6  $\log_2$ PRNT (95% CI 7.1 – 8.1). The highest PRNT titre observed among these participants was 12.9  $\log_2$ PRNT while the lowest was 5.1  $\log_2$ PRNT.

### QA results

The mean PRNT titre results of a panel of 5 reference samples from BEI Resources tested in our laboratory were within range

of the PRNT titre results as tested in BEI in 2011. These results are shown in [Table 1](#).

### Comparison of ELISA with PRNT

A Pearson correlation test to determine the strength of association between ELISA antibodies and neutralizing antibody ([Figure 1](#)), showed a strong positive correlation between PRNT titres and IBL ELISA antibody ( $r=0.75$ ), and moderate positive correlation between PRNT titres and crude ELISA antibody ( $r=0.61$ ). The two correlations were each statistically significant ( $P=0.0001$ ).


The distribution of log transformed RSV antibody concentrations were approximately log- normal for each ELISA dataset and for the PRNT data. Bland-Altman plots were drawn to assess the agreement between PRNT and ELISA in quantifying a high or low RSV specific antibody level from a sample ([Figure 2](#)). In this analysis, 95% of samples were observed to fall within the 95% level of agreement between PRNT and IBL ELISA and 96% of samples between PRNT and crude ELISA, respectively. The Bland-Altman plots showed a mean difference of 4.5  $\log_2$  PRNT (95% limits 1.3-7.6) between PRNT and IBL ELISA and 2.1  $\log_2$  PRNT (95% limits -1.9-6.2) between PRNT and crude ELISA. Crude RSV lysate IgG ELISA showed a slightly wider 95% limit of agreement (-1.866, 6.157) compared to IBL RSV IgG ELISA (1.392, 7.595).

Modified Bland-Altman plots ([Figure 3](#)) show the difference in value of the ELISA and PRNT results plotted against age in months (i.e. time since birth of collection of the samples). Age did not have any appreciable effect on the agreement between PRNT and either of the ELISA result.


Further assessment using regression analysis ([Figure 4](#)), estimated the standard error for predicting the mean PRNT titres by ELISA

**Table 1. Neutralisation test results by Kenya Medical Research Institute KEMRI-Wellcome Trust Research Programme (KEMRI-WTRP) and BEI laboratories of samples from BEI Resources respiratory syncytial virus (RSV) Reference panel catalogue #NR-32832 which contains 5 different pooled human polyclonal antisera to RSV.**


Reference sample	Expected titer range provided by BEI	KEMRI-WTRP
	in 2011	Mean $\log_2$ neut titer
BEI NR-4020 Wyeth lot 6594	8.79 ( $\pm 6.48$ )	8.93 (8.61-9.20)
BEI NR-4021 Wyeth lot 6937 - high	10.88 ( $\pm 9.75$ )	10.29 (9.91-10.60)
BEI NR-4022 Wyeth lot 6938 - medium	7.81 ( $\pm 5.81$ )	8.75 (8.12-9.19)
BEI NR-4023 Wyeth lot 6939 - low	8.28 ( $\pm 2.81$ )	8.73 (8.25-9.08)
BEI NR-21973 CBER reference Ig lot RSV-1	7.56 ( $\pm 5.21$ )	8.59 (8.09-8.96)
Palivizumab (Synagis) 100 mg/ml		(Assayed a 1% solution of stock Ab) 10.59 (10.43-10.73) Undiluted = 17.23




**Figure 1.** Scatter plots showing correlation between: **(a)** Commercial IBL respiratory syncytial virus (RSV) IgG ELISA and plaque reduction neutralisation test (PRNT) RSV antibody titres **(b)** Crude RSV lysate IgG ELISA antibody and PRNT RSV antibody titres. The spearman correlation coefficient ( $r$ ) is shown. ELISA IgG antibodies are presented using base10 log scale, while PRNT RSV antibodies are presented using base 2 log scale.



**Figure 2.** Bland Altman plots showing agreement between: **(a)** Commercial IBL respiratory syncytial virus (RSV) IgG ELISA and plaque reduction neutralisation test (PRNT) RSV antibody titres **(b)** Crude RSV lysate IgG ELISA antibody and PRNT RSV antibody titres. The 95% limits of agreement, mean difference and averages are also shown for each graph. PRNT and ELISA IgG antibodies are presented using base2 log scale.



**Figure 3. Modified Bland Altman scatter plot showing the effect of age on agreement between plaque reduction neutralisation test (PRNT) and ELISA assays.** Panel **A** is a graph for difference between PRNT and Commercial IBL respiratory syncytial virus (RSV) IgG ELISA against age and panel **B** is a graph for difference between PRNT and Crude RSV lysate IgG ELISA against age. The short dashed gray lines represent the 95% limits of agreement, solid gray line represent the mean difference of agreement for each graph. PRNT and ELISA IgG antibodies are presented using base2 log scale.



**Figure 4. Scatter plots and regression analysis showing respiratory syncytial virus (RSV) specific antibody predictions between: (a) IBL RSV IgG ELISA and plaque reduction neutralisation test (PRNT) RSV antibody titres (b) Crude RSV lysate IgG ELISA antibody and PRNT RSV antibody titres.** The 95% prediction intervals are shown for each graph by blue dashed lines, while the predicted mean for PRNT measurements by ELISA are shown using continuous black line. Black hollow circles represent individual antibody levels. ELISA IgG antibodies are presented using base10 log scale, while PRNT RSV antibodies are presented using base 2 log scale.

method to be 1.204 and 1.424 for IBL ELISA and crude ELISA, respectively. All samples with low concentrations of RSV specific antibody were within the 95% prediction limit for crude RSV lysate IgG ELISA (Figure 4b). The predicted PRNT values by IBL ELISA were given as  $(1.880x + 6.517)$ , while the predicted PRNT values by crude ELISA were given as  $(1.419x + 6.164)$ . The 95% prediction limits for PRNT antibodies were slightly higher for crude ELISA  $\pm 2.79 \log_2$  PRNT compared to IBL ELISA  $\pm 2.36 \log_2$  PRNT.

## Discussion

To overcome the challenges experienced with PRNT as a technique for quantifying protective immunity correlates to RSV in large vaccine studies, we explored how well ELISA and PRNT methods agree in detecting levels of RSV specific antibodies, and in addition, investigated how accurate an ELISA method can predict the PRNT measurements and if it could be considered a suitable replacement for PRNT.

We found moderate to good correlations between each ELISA (IBL ( $r=0.75$ ) and crude ( $r=0.61$ )) and the reference method for neutralizing antibodies, PRNT. The stronger correlation in IBL ELISA could be explained by the fact that, both PRNT and IBL ELISA methods were designed to target specific antibodies against the RSV F and G protein. This is because, neutralising antibodies are presumed to dominate within the RSV F protein also commonly known as the key target for neutralizing antibodies<sup>24,25</sup>. Consequently, there is increasing interest to use the RSV F protein as the maternal RSV vaccine candidate antigen<sup>7</sup>. The moderate correlation with crude ELISA is likely caused by the wide range of antibodies against multiple RSV antigens the assay targets. This might have possibly led to detection of additional antibodies specific to other RSV proteins that are missed by both IBL ELISA and PRNT assay.

We identified few studies that show correlation between ELISA and neutralization assay<sup>26–29</sup>. Similar findings to our study were previously reported by Welch *et al*, who suggested that ELISA measure all antibody types and do not discriminate the neutralizing antibodies as measured by functional assays, thus cannot be relied upon to predict the neutralizing activity of the sera<sup>29</sup>. Due to the moderate correlation observed in our study between PRNT and crude RSV lysate IgG ELISA, we suggest that, careful consideration should be made on the choice of ELISA based assays as a surrogate for a neutralization assay in epidemiological studies.

The Bland-Altman plots demonstrated that 96% of all samples fell into the 95% limits of agreement between PRNT and crude ELISA. However, the crude ELISA had a slightly wider limit of agreement with PRNT compared to IBL ELISA. The PRNT values were also consistently higher than for ELISA. The wider limit of agreement indicates that the crude RSV lysate IgG ELISA has a higher variability with PRNT compared to IBL ELISA. This again, raises the issue of specificity and affinity of binding for RSV specific IgG antibodies measured using the crude ELISA method. Very few studies have used Bland-Altman plots to assess agreement between two serological methods<sup>29–32</sup>.

One study which evaluated two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies<sup>29</sup>, suggested that the results from the Bland-Altman plot analysis can only offer an insight into the availability of alternative, less complex method to monitor antibody titres during vaccine studies.

We also demonstrated that age did not have an appreciable effect on the agreement between PRNT and ELISA methods in detection of RSV specific antibodies. We performed this analysis because poor correlation between functional antibody and antibody concentration is thought to be influenced by age<sup>33</sup>. For instance, samples from infants and the elderly are likely to show a poor correlation between PRNT and ELISA usually because their receptors don't activate appropriate T or B cell responses, although the antibodies bind to antigen<sup>33</sup>. However, in this study, both methods showed agreement in the level of detected antibody for an individual regardless of age.

In this study, we could predict PRNT titres using ELISA with moderate accuracy. Using regression analysis, the IBL ELISA method predicted the mean PRNT titre at 95% prediction interval within a width of  $4.8 \log_2$  PRNT, while, crude RSV lysate IgG ELISA predicted the mean PRNT titre within a width of  $5.6 \log_2$  PRNT units. This implies that, the PRNT titre of any given serum sample if estimated using an ELISA IgG antibody concentration measured directly by the ELISA method would fall within 2.4–2.8 fold higher or lower than the true value. In a perfect regression, if RSV antibody concentrations were measured by ELISA, the corresponding PRNT values would be estimated using  $(1.880x + 6.517)$  and  $(1.419x + 6.164)$  for IBL ELISA and crude ELISA respectively. With,  $x$  being the antibody concentration measured directly by the respective ELISA method. However, the high variability makes direct estimation of PRNT values by the above formula difficult. For instance, the 95% upper limit of detecting mean cord PRNT titre of  $10.6 \log_2$  PRNT by crude ELISA would be  $13.4 \log_2$  PRNT, which is above the highest value ( $12.9 \log_2$  PRNT) the PRNT assay detected in this study. The combined analysis approach we have applied on the data is unique and we think, this could better guide the choice of a suitable serological technique for use in place of a PRNT assay for large vaccine studies; and especially if the units of measurements between the two methods are different.

The main limitation we highlight in this study is that the PRNT assay we are using is difficult to standardize, which complicates comparison of results between laboratories. However, during the time this study was conducted there was no RSV standard available. Nevertheless, we tried to mitigate this limitation by using a panel of reference serum samples from BEI resources to monitor and minimise assay variability and to make sure results of the test samples obtained are acceptable. Another limitation is the systematic bias observed with analysis using Bland-Altman plots. This was due to the differences in metrics used to measure RSV specific antibodies by ELISA and PRNT. The RSV specific antibodies in ELISA are measured as a concentration ( $\log_{10}$ ) while in PRNT assay are measured as



titres (log<sub>2</sub>). The Bland-Altman plots show a trend if analysis is done using the respective metrics of the serological assays, thus difficulty in estimating the mean difference. The plots in Bland-Altman analysis should demonstrate that the two methods are consistent in what they are measuring in the same metrics. We tried to minimise this by transforming ELISA values to log base 2 during Bland-Altman plot analysis.

## Conclusions

Both ELISA methods show a moderate-good correlation with PRNT in measuring RSV specific antibodies. However, a commercial anti RSV based ELISA antibody assay which has less variability and has a high positive correlation with PRNT assay in detecting RSV specific antibody responses, does not provide an accurate prediction of PRNT antibody values. The true PRNT value would lie 2.4 fold higher or 2.4 fold lower if a commercial RSV IgG IBL ELISA is used in place of a PRNT assay. Our results suggest that, should PRNT prove unsuitable as a Gold standard for quantifying RSV specific antibodies, the utility of an ELISA method in vaccine studies should be assessed independent of a PRNT assay.

## Data availability

### Underlying data

The raw data is stored under restricted access and available from the authors upon request through submission of a request form [http://kemri-wellcome.org/aboutus/#ChildVerticalTab\\_15](http://kemri-wellcome.org/aboutus/#ChildVerticalTab_15) for consideration by our Data Governance Committee ([dgc@kemri-wellcome.org](mailto:dgc@kemri-wellcome.org)).

Harvard Dataverse: Replication Data for: Agreement between ELISA and Plaque Reduction Neutralisation Assay in Detection of Respiratory Syncytial Virus Specific Antibodies in a Birth

Cohort from Kilifi, Coastal Kenya. <https://doi.org/10.7910/DVN/K3LS7M><sup>34</sup>

This project contains the following underlying data:

- NEUT ELISA Analysis script.do
- NEUT ELISA data codebook.pdf
- NEUT ELISA data file.tab
- NEUT ELISA\_Data Readme txt.txt

Data are available under [Creative Commons Attribution 4.0 International \(CC BY 4.0\) Licence](https://creativecommons.org/licenses/by/4.0/)

## Grant information

This work was supported by the Wellcome trust [102975 and 084633].

This work was also supported by PATH [GAT.1387-05695-COL].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

## Acknowledgements

We thank all the study participants for their contribution of study samples. We are also grateful to field, laboratory and data management staff of the KEMRI Wellcome Trust Research Programme for collection and storage of the samples and data retrieval. We sincerely thank Dr. Patricia Cane for her kind donation of RSVA2 virus and Hep2 cells. We highly appreciate the statistical advice provided by Dr. Eric Ohuma of University of Oxford, UK. This paper is published with the permission of the Director of KEMRI.


## References

1. Lee MS, Walker RE, Mendelman PM: **Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.** *Hum Vaccin.* 2005; 1(1): 6–11. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Cooney MK, Fox JP, Hall CE: **The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and *Mycoplasma pneumoniae*.** *Am J Epidemiol.* 1975; 101(6): 532–551. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Noyola DE, Arteaga-Dominguez G: **Contribution of respiratory syncytial virus, influenza and parainfluenza viruses to acute respiratory infections in San Luis Potosi, Mexico.** *Pediatr Infect Dis J.* 2005; 24(12): 1049–1052. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Chanock R, Chambon L, Chang W, *et al.*: **WHO respiratory disease survey in children: a serological study.** *Bull World Health Organ.* 1967; 37(3): 363–369. [PubMed Abstract](#) | [Free Full Text](#)
5. Nair H, Nokes DJ, Gessner BD, *et al.*: **Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.** *Lancet.* 2010; 375(9725): 1545–55. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Nokes DJ, Ngama MJ, Bett A, *et al.*: **Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance.** *Clin Infect Dis.* 2009; 49(9): 1341–1349. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Raghunandan R, Lu H, Zhou B, *et al.*: **An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.** *Vaccine.* 2014; 32(48): 6485–6492. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Piedra PA, Jewell AM, Cron SG, *et al.*: **Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.** *Vaccine.* 2003; 21(24): 3479–3482. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Sande CJ, Mutunga MN, Medley GF, *et al.*: **Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia.** *J Infect Dis.* 2013; 207(3): 489–492. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Nyiro JU, Sande C, Mutunga M, *et al.*: **Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.** *Vaccine.* 2015; 33(15): 1797–1801. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Suara R, Piedra PA, Glezen WP, *et al.*: **Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States.** *Clin Diagn Lab Immunol.* 1996; 3(4): 477–479. [PubMed Abstract](#) | [Free Full Text](#)
12. Glezen WP, Paredes A, Allison JE, *et al.*: **Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex,**

- ethnic group, and maternal antibody level. *J Pediatr.* 1981; **98**(5): 708–715.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Roca A, Abacassamo F, Loscertales MP, *et al.*: **Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique.** *J Med Virol.* 2002; **67**(4): 616–623.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  14. Piedra PA, Hause AM, Aideyan L: **Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection.** *Methods Mol Biol.* 2016; **1442**: 77–91.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  15. Pastrana DV, Buck CB, Pang YY, *et al.*: **Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.** *Virology.* 2004; **321**(2): 205–216.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  16. Stensballe LG, Simonsen JB, Thomsen SF, *et al.*: **The causal direction in the association between respiratory syncytial virus hospitalization and asthma.** *J Allergy Clin Immunol.* 2009; **123**(1): 131–137.e1.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  17. Hosken N, Plikaytis B, Trujillo C, *et al.*: **A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard.** *Vaccine.* 2017; **35**(23): 3082–3088.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  18. Nokes DJ, Okiro EA, Ngama M, *et al.*: **Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life.** *J Infect Dis.* 2004; **190**(10): 1828–1832.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  19. English M, Muhoro A, Aluda M, *et al.*: **Outcome of delivery and cause-specific mortality and severe morbidity in early infancy: a Kenyan District Hospital birth cohort.** *Am J Trop Med Hyg.* 2003; **69**(2): 228–232.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  20. Scott JA, Bauni E, Moisi JC, *et al.*: **Profile: The Kilifi Health and Demographic Surveillance System (KHDSS).** *Int J Epidemiol.* 2012; **41**(3): 650–657.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  21. Ochola R, Sande C, Fegan G, *et al.*: **The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.** *PLoS One.* 2009; **4**(12): e8088.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  22. Nyiro JU, Kombe IK, Sande CJ, *et al.*: **Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.** *PLoS One.* 2017; **12**(5): e0177803.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  23. Bland JM, Altman DG: **Applying the right statistics: analyses of measurement studies.** *Ultrasound Obstet Gynecol.* 2003; **22**(1): 85–93.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  24. McLellan JS, Yang Y, Graham BS, *et al.*: **Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.** *J Virol.* 2011; **85**(15): 7788–7796.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  25. Taleb SA, Al Thani AA, Al Ansari K, *et al.*: **Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.** *Eur J Clin Microbiol Infect Dis.* 2018; **37**(10): 1817–1827.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  26. Westenbrink F, Brinkhof JM, Straver PJ, *et al.*: **Comparison of a newly developed enzyme-linked immunosorbent assay with complement fixation and neutralisation tests for serology of bovine respiratory syncytial virus infections.** *Res Vet Sci.* 1985; **38**(3): 334–340.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  27. Rabenau HF, Marianov B, Wicker S, *et al.*: **Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations.** *Med Microbiol Immunol.* 2007; **196**(3): 151–155.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  28. Zhao H, Lin ZJ, Huang SJ, *et al.*: **Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.** *Hum Vaccin Immunother.* 2014; **10**(3): 740–746.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  29. Welch RJ, Anderson BL, Litwin CM: **An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies.** *J Med Microbiol.* 2009; **58**(Pt 6): 806–810.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  30. Welch RJ, Litwin CM: **Evaluation of two immunoblot assays and a Western blot assay for the detection of antisyphilis immunoglobulin g antibodies.** *Clin Vaccine Immunol.* 2010; **17**(1): 183–184.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  31. Weissbach FH, Hirsch HH: **Comparison of Two Commercial Tick-Borne Encephalitis Virus IgG Enzyme-Linked Immunosorbent Assays.** *Clin Vaccine Immunol.* 2015; **22**(7): 754–760.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  32. Parreiras PM, Sirota LA, Wagner LD, *et al.*: **Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.** *Vaccine.* 2009; **27**(33): 4537–4542.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  33. Metcalf TU, Cubas RA, Ghneim K, *et al.*: **Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors.** *Aging Cell.* 2015; **14**(3): 421–432.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  34. Nyiro JU, Mwangi L, Nokes DJ: **Replication Data for: Agreement between ELISA and Plaque Reduction Neutralisation Assay in Detection of Respiratory Syncytial Virus Specific Antibodies in a Birth Cohort from Kilifi, Coastal Kenya**. Harvard Dataverse, V1, UNF:6cXM/Pb4otN6UNHbP6wuvDA== [fileUNF]. 2019. <http://www.doi.org/10.7910/DVN/K3LS7M>

# Open Peer Review

Current Referee Status:



Version 1

Referee Report 21 March 2019

<https://doi.org/10.21956/wellcomeopenres.16484.r34954>



**Pedro A. Piedra**

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

### Overall comment.

The major objective of this manuscript was to determine if at least one of the two in house RSV ELISA assays could predict with accuracy the neutralizing antibody titers generated by a plaque reduction neutralization test (PRNT). Although the methodology used to make the comparisons and analytical approach used to make the prediction are sound, the basic assumption is flawed when using crude or poorly described viral antigens in the ELISA assays. The neutralization assay primarily measures neutralizing antibodies directed to site-specific sites on the F protein while the ELISA assay using viral antigens will measure binding antibodies direct to the surface glycoproteins (F, G & SH) as well as the internal proteins (N, P, M, M2). Although good correlations are normally seen between ELISA and neutralization assays, it is entirely a different proposition to predict with accuracy neutralizing antibody titers when using viral antigens in an ELISA assay. Even site-specific competitive antibody assays to the F protein are not able to predict with accuracy neutralizing antibody tiers measured by neutralization assays because the immune response of individuals vary to the antigenic sites (Ø, II, IV, III, V) of the F protein even though they may have comparable neutralizing antibody activity. The lack of precision was evident in the results with the potential to have up to a 16 to 32-fold swing in the neutralizing antibody titer prediction using the ELISA assays.

### Other comments.

In the manuscript PRNT is described as the preferred technique to determine immune correlates of protection. It is important to point out that the PRNT is one of many neutralization assays that have been developed for measuring neutralizing antibody activity against RSV. There are two major classes of neutralization assays; the PRNT and the microneutralization assay. There are many assay variations depending on the cell line, the virus inoculum, the signal or read out used to measure neutralizing activity, the duration of the assay, etc. Many of the PRNT references used in the manuscript actually refer to the classical microneutralization assay. It is also important to note that these neutralization antibody assays, in particular those without complement, primarily detect neutralizing antibody directed to the F protein and not the G protein.

Neutralization assays are considered the best current method to evaluate the protective potential (neutralizing antibodies) induced by RSV infection or candidate vaccines. We now have an international standard (National Institute of Biological Standards and Control-NIBSC) against RSV/A (also being developed for RSV/B) that can be used to adjust neutralizing antibody titers generated by different neutralization assays into IU. This will greatly facilitate the comparisons of neutralizing antibody activity measured by different assays and induced by different candidate vaccines. The introduction section

should be revised to reflect these up-dates.

### Introduction.

The Fusion (F) protein in Novavax F nanoparticle vaccine is not a true post-fusion F protein vaccine. It is consistent with a prefusogenic form that is able to generate site-specific antibody responses to both the pre-fusion and post-fusion F conformations<sup>1</sup>.

### Method.

What was the collection tube used to process plasma? Plasma collected in heparin coated tubes will inaccurately measure plasma samples with low neutralizing antibody activity to RSV because heparin containing plasma will act as an antiviral agent. The effect is to inhibit virus replication when in reality there is no neutralizing antibody activity. This is unlikely to have an effect with plasma samples with moderate to high levels of neutralizing antibody titers against because the effect is diluted out with increasing two-fold dilutions.

For the ELISA assays it is unclear what the dilution scheme was for generating the ELISA units. The results are presented in log<sub>10</sub>, which suggest a dilution scheme of 10-fold. Please clarify the dilution scheme for the two ELISA assays. Also for all the assays please describe the range of the antibody titer and arbitrary unit for the assays. It would also be helpful to know the coefficient of variation for these assays at the lower limit of detection, dynamic range and upper limit of detection.

It is unclear the viral antigen(s) included in the IBL ELISA assay. The information is not provided in the IBL package insert.

### Results.

It is a misnomer to call it an RSV-F ELISA. Please see Y axis for Figures 2 and 3.

Figures 2 & 3, Y axis is the difference (PRNT – RSV F protein ELISA) in log<sub>2</sub>?

What was the correlation between the two ELISA assays, and did one ELISA assay predict with good accuracy the AU of the other ELISA assay. That would serve as an internal validation of the statistical method used to predict neutralizing antibody titer with ELISA bind antibody data.

### Discussion.

Page 8, 7<sup>th</sup> paragraph, “predict with moderate accuracy”. Having a width of 4.8 log to 5.6 log<sub>2</sub> is huge and should be considered imprecise.

In my opinion, the main limitation is not the standardization of the PRNT but rather the assumption that accurate predictions can be made when using ELISA assays with poorly characterized viral antigens. A second major limitation is the use of immunological assays that do not appear to have been qualified. Information on the reproducibility, dynamic range, lower and upper limit of detection were not provided for these assays.

### References

1. Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G: Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. *Vaccine*. 2018; **36** (52): 8069-8078 [PubMed Abstract](#) | [Publisher Full Text](#)

### Is the work clearly and accurately presented and does it cite the current literature?

Partly

### Is the study design appropriate and is the work technically sound?

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Epidemiology, immunology, clinical trials on RSV and other respiratory viruses.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Referee Report 19 March 2019

<https://doi.org/10.21956/wellcomeopenres.16484.r34920>



**Helen Y. Chu**

Department of Medicine, University of Washington, Seattle, WA, USA

This is an important study which addresses the question of whether RSV ELISAs can replace neutralizing antibody assays for use in vaccine trials. This study analyzes the agreement between and accuracy of measuring RSV specific antibodies using ELISA w/ crude RSV lysate and RSV IgG ELISA in comparison with the current “gold standard” method for measuring RSV specific antibodies, a plaque reduction neutralization test (PRNT). In previous studies, ELISA and PRNT have not been shown to correlate well, due to non-neutralizing antibodies.

Methodologically, the study is sound. Comparison was made between the PRNT, utilizing a method that has been used by multiple labs. Results from a standardized set of reference sera are included, showing performance of the test within range. Comparison was made against a commercial and in-house ELISA. Samples tested included sera samples from the cord blood of 99 participants and subsequent 3 and 6-month samples from a fraction of these participants. Strength of association was calculated with a correlation test and agreement between PRNT and ELISA were examined on Bland-Altman plots.

Results demonstrated a relatively high correlation was seen between the crude RSV Lysate ELISA and PRNT, and a more moderate correlation was observed between the RSV IgG ELISA and PRNT. Overall, this is an important study in the setting of multiple new vaccine and antibody prophylaxis candidates in clinical trials, for which it would be immensely helpful to have a less expensive, less labor-intensive method of measuring antibody as a correlate of protection.

Overall the commercial ELISA had higher correlation as compared to the ELISA using crude RSV A2

lysate, which as the authors point out, is likely due to targeting of F and G antigen in the commercial assay. Despite this higher correlation, the margin of error for the formula calculating the relationship between the ELISA and the PRNT is too high to be useful. This is a useful study, and reaffirms the use of RSV neutralizing antibody assays as the gold standard. One minor criticism, largely outside the scope of this study, is the consideration of other correlates of protection beyond neutralizing antibody as markers of protection against disease.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Respiratory syncytial virus

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 06 March 2019

<https://doi.org/10.21956/wellcomeopenres.16484.r34921>



**Shabir Madhi** 

University of Witwatersrand, Johannesburg, South Africa

This study evaluated the agreement between the RSV plaque reduction neutralisation assay (PRNT), a commercially available RSV IgG ELISA assay and an in-house RSV assay using crude RSV lysate as an antigen.

General comments:

1. Overall, the methods and results section of the manuscript are well written and analysed.
2. Although the study objective is clear, the rationale for the study is more ambiguous. The main issue at hand in the context of vaccine development, is the need for an assay which can predict the efficacy of the vaccine –and ideally a functional assay or at least one that bridges with a functional assay. This would be important for bridging studies, in the absence of being able to undertake multiple large scale vaccine efficacy/effectiveness studies. Although the authors cite some studies

reporting a positive association of PRNT antibody and risk/odds of disease, omitted from the background are other studies (including one from the same group)- which actually reported no association between PRNT and RSV LRTI. This calls into question the value of the current “gold standard”- i.e PRNT- on its own (over and above the issues with regard to standardisation and being labour intensive) in relation to whether or not it would be useful for establishing a correlate of protection.

In the context of this study where the ELISA assays, as also noted by the authors, are not discriminatory in terms of measure of antibody to epitopes specifically targeted by most of the vaccines currently under clinical development (including the nanoparticle F-fusion vaccine), the likelihood of any predictive value of a relatively non-specific ELISA assay being of use to establish or impute a correlate of protection would be doubtful from the outset.

These issue merit inclusion in the abstract, study rational and the discussion.

3. The measure of RSV antibody could have multiple purposes- including characterising sero-epidemiology, measuring vaccine immunogenicity or trying to establish a correlate of protection. Depending on for what purpose the assay is being used, would influence the minimum characteristics required of the assay. In the context of this study, although the ELISA assays were only moderately predictive of the PRNT antibody measure, this does not necessarily preclude the use thereof in sero-epidemiology studies. Likewise, even if there was a strong correlation between the ELISA and PRNT assays, in the absence of an established correlate of protection using the PRNT assay- that too would not be of much value in terms of being used for studies to impute vaccine effectiveness in different settings.

#### Specific comments

1. Pg 3 end para 2- need to clarify that the standardised assays which are required need to be assays that are predictive of vaccine protection. Also, clarify that the main purpose of such assays are to undertake “bridging immunogenicity studies” to avoid multiple vaccine efficacy/effectiveness studies. Such assays will need to be tested for predicting vaccine efficacy often within a clinical trial and the assays could differ based on the construct of the vaccine (i.e differences in specific epitopes targeted).
2. Pg 3 para 3- mention and reference studies that have shown no association between PRNT and LRTI.
3. Pg 3 para 4- clarify that the needs of an assay for sero-epi studies may well differ to those required to establish a correlate of protection.
4. Pg 3 para 5- what would the need for a serological assay be in a “large vaccine efficacy trial” which will provide the most definitive answer on vaccine efficacy?
5. Under lab methods- clarify where the lab assays were done.
6. Pg 8 para 3- neutralizing antibodies are also elicited by immune responses to the G and M protein. This might well explain some of the conflicting findings on the association of PRNT and risk for RSV LRTI.
7. Pg 8 para 4- the last sentence needs to be elaborated upon, including what the possibility for epitope specific antibody read-outs that might well differ between vaccine constructs.

#### **Is the work clearly and accurately presented and does it cite the current literature?**

Partly

#### **Is the study design appropriate and is the work technically sound?**

Yes

#### **Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

No source data required

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Epidemiology, immunology and clinical trials on vaccine preventable diseases, with focus on respiratory pathogens.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Referee Report 05 March 2019

<https://doi.org/10.21956/wellcomeopenres.16484.r34922>



**Ting Shi** 

University of Edinburgh, Edinburgh, UK

This study investigates how well ELISA and PRNT methods agree in detecting levels of RSV specific antibodies (also accuracy) and whether an ELISA method can be an appropriate replacement for PRNT. Generally it is well written and I only have minor comments listed as follows:

1. Can you please justify the sample size you selected for the purpose of this study?
2. You mentioned that age did not have a substantial effect on the agreement between PRNT and ELISA methods. As age advances, will you expect the similar finding?
3. What is your opinion of applying the similar ELISA methods quantifying RSV specific antibodies beyond young children? e.g. older adults?
4. Will different clinical specimen make an influence on the agreement / accuracy of ELISA methods?
5. What is the next step (research question) based on findings from this study?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes



**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

***Competing Interests:*** No competing interests were disclosed.

***Reviewer Expertise:*** respiratory infection, epidemiology

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---